Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Denise Connolly

Center AffiliationsMolecular Therapeutics

Publications (44) (print view)

no pagination
Ratushny V, Pathak HB, Beeharry N, Tikhmyanova N, Xiao F, Li T, Litwin S, Connolly DC, Yen TJ, Weiner LM, Godwin AK, Golemis EA. Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. Oncogene. 2012 Mar 08;31(10):1217-27.   PMCID: PMC3204164
Rozmiarek H, Connolly DC. Response to Protocol Review Scenario: Specify all medications. Lab Anim (NY). 2011 Mar;40(3):66-7.   PMCID: not NIH funded
Deng S, Yang XJ, Lassus H, Liang S, Kaur S, Ye QR, Li CS, Wang LP, Roby KF, Orsulic S, Connolly DC, Zhang YC, Montone K, Butzow R, Coukos G, Zhang L. Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 (ALDH1), in Human Epithelial Cancers. Plos One. 2010 Apr;5(4):E10277.   PMCID: PMCID: PMC2858084
Williams RM, Flesken-Nikitin A, Ellenson LH, Connolly DC, Hamilton TC, Nikitin AY, Zipfel WR. Strategies for High-Resolution Imaging of Epithelial Ovarian Cancer by Laparoscopic Nonlinear Microscopy. Translational Oncology. 2010 Jun;3(3):181-94.   PMCID: PMCID: PMC2887648
Connolly DC. Animal models of ovarian cancer. Cancer Treat Res. 2009 Jan;149:353-91.
Connolly DC, Hensley HH. Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents. Curr Protoc Pharmacol. 2009 Jun;45:14 12 1-14 12 26.   PMCID: PMC2904083
Izumchenko E, Singh MK, Plotnikova OV, Tikhmyanova N, Little JL, Serebriiskii IG, Seo S, Kurokawa M, Egleston BL, Klein-Szanto A, Pugacheva EN, Hardy RR, Wolfson M, Connolly DC, Golemis EA. NEDD9 Promotes Oncogenic Signaling in Mammary Tumor Development. Cancer Research. 2009 Sep;69(18):7198-206.   PMCID: PMC2768619
Quinn BA, Brake T, Hua X, Baxter-Jones K, Litwin S, Ellenson LH, Connolly DC. Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PLoS One. 2009 Jan;4(12):e8404.   PMCID: 2796165
Choi YS, Hoory T, Monie A, Wu A, Connolly D, Hung CF. alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors. Vaccine. 2008 Oct;26(46):5855-63.
Hensley H, Quinn BA, Wolf RL, Litwin SL, Mobuchi S, Williams SJ, Williams C, Hamilton TC, Connolly DC. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biology & Therapy. 2007 Nov;6(11):1717-25.
Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC, Testa JR. RAD001 (Everolimus) Delays Tumor Onset and Progression in a Transgenic Mouse Model of Ovarian Cancer. Cancer Res. 2007 Mar 15;67(6):2408-13.
Disis ML, Rivkin SE, Baron A, Markman M, Connolly D, Ueland F, Kohn E, Trimble E, Berek JS. Progress in ovarian cancer research: Proceedings of the 5th biennial ovarian cancer research symposium. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2006 Mar;16(2):463-9.
Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT. Mullerian inhibiting substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 2006 Nov;103(46):17426-31.
Pieretti-Vanmarcke R, Donahoe PK, Szotek P, Manganaro T, Lorenzen MK, Lorenzen J, Connolly DC, Halpern EF, MacLaughlin DT. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. CLINICAL CANCER RESEARCH. 2006 Mar;12(5):1593-8.
Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9.
Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescut DM, Connolly D, Foster R, Dombkowski D, Preffer F, MacLaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2006 Jul;103(30):11154-9.
Danielsen AJ, Christensen TA, Lovejoy CA, Adelsman MA, Connolly DC, Maihle NJ. Membrane localization of v-ErbB is required but not sufficient for ligand-independent transformation. Experimental Cell Research. 2004 Jun 10;296(2):285-93.
Nikitin AY, Connolly DC, Hamilton TC. Pathology of ovarian neoplasms in genetically modified mice. Comparative medicine. 2004 Feb;54(1):26-8.
Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu XX, Hamilton TC. Focus on epithelial ovarian cancer. Cancer cell. 2004 Jan;5(1):19-24.
Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, Hamilton TC. Female Mice Chimeric for Expression of the Simian Virus 40 TAg under Control of the MISIIR Promoter Develop Epithelial Ovarian Cancer. Cancer Res. 2003 Mar 15;63(6):1389-97.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

Denise Connolly Sparkline Graph

Graph Interactions


Similar Investigators:

Keywords (MeSH):

Last updated on Monday, June 03, 2019